Posted by Michael Wonder on 21 Feb 2026
FDA approves acalabrutinib with venetoclax for chronic lymphocytic leukaemia or small lymphocytic lymphoma
20 February 2026 - On 19 February 2026, the FDA approved acalabrutinib (Calquence, AstraZeneca) tablets and capsules in combination with venetoclax (Venclexta, AbbVie and Genentech) for adults with chronic lymphocytic leukaemia or small lymphocytic lymphoma.
Efficacy was evaluated in AMPLIFY, a randomised, multi-center trial in adult patients previously untreated for chronic lymphocytic leukaemia without del(17p) or TP53 mutation.
